Xiumin Cui

Xiumin Cui is an experienced Senior Research Scientist with a strong background in the pharmaceuticals industry, focusing on sterile injectable formulation development. They served as a project lead at FORESEE PHARMACEUTICALS USA, INC. from 2016 to 2019, overseeing cancer therapy drug formulation following FDA and ICH regulations. Xiumin has contributed to various organizations, including DuPont, Moderna, and Orchestra BioMed, and currently holds the position of Associate Principal Scientist at Merck, where they focus on biologics commercialization. They earned a Ph.D. in Pharmaceutical Sciences from the University of the Sciences in Philadelphia and possess certifications in Regulatory Affairs and Quality Assurance.